A nonsynonymous variant in PNPLA3 has been associated with steatosis, steatohepatitis and hepatic fibrosis and its deregulation can lead to increased hepatocellular triglyceride accumulation, impairing lipid remodeling and turnover [45] and development of NAFLD [46]. Here, PNPLA3 is linked to steatosis.